In the notice under its Transmucosal Immediate-Release Fentanyl Medicines program, the agency stated that all TIRF medications would be discontinued starting Sept. 30.
“Prescribers currently certified in the TIRF REMS may continue to prescribe TIRF therapy for their currently enrolled patients while supplies remain but must begin working with their patients to transition to other non-TIRF treatments,” the statement read.
The FDA has not issued any statements about the TIRF discontinuations or its decision to end the program.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
